2026 年 1 月 5 日 公司研究 专注女性健康和美，"医疗+消费"双轮驱动 ——麦澜德（688273.SH）投资价值分析报告 要点 深耕盆底康复十余载，拓展女性全生命周期健康和美。公司成立于 2013 年，是 国内女性盆底功能障碍（PFD）市场的领导品牌。公司聚焦盆底及妇产康复器械 的研产销，拓展生殖抗衰、运动康复、轻医美、脑机接口等领域，通过自研和并 购，快速构建女性全生命周期产品矩阵。公司拥有聚焦超声、激光、电生理、电 刺激、磁刺激、高频等多种能量源技术，持续引领行业发展。截至 2025H1 末， 公司覆盖超 8700 家医院、6000 家院外专业机构，核心高管持股超 60%。 2018-2024 年公司营收/归母净利润 CAGR 为 19.8%/10.4%。 产品领先+渠道高效，盆底康复基本盘稳固。我国女性 PFD 患病率高，但就诊率 和治疗率低，潜在患者超 2.8 亿人，市场需求广阔。物理治疗为主流疗法，盆底 康复器械技术日益成熟。公司作为该领域龙头，已构建"筛查-评估-治疗-居家康 复"全闭环服务，并前瞻布局脑机接口等技术，其自主研发的 AI 辅助盆底生殖 康复诊治系统达"国际领先水平"，推动 ...

Core Viewpoint - Nanjing Medlander Medical Technology Co., Ltd. reported a revenue increase of 5.62% in the first half of 2025, but net profit decreased by 11.96%, indicating challenges in profitability despite revenue growth [3][14]. Company Overview - Nanjing Medlander specializes in the research, production, and sales of rehabilitation medical devices, focusing on pelvic and gynecological rehabilitation [8][14]. - The company has established a comprehensive ecosystem for pelvic and gynecological rehabilitation, integrating products, services, education, and data [8][14]. Financial Performance - The company achieved an operating income of approximately 241.22 million yuan in the first half of 2025, compared to 228.38 million yuan in the same period of the previous year [3]. - Total profit for the period was approximately 71.20 million yuan, down from 85.23 million yuan year-on-year, reflecting a decline of 16.46% [3]. - The net profit attributable to shareholders was approximately 63.92 million yuan, a decrease of 11.96% from the previous year [3]. Industry Context - The medical device industry in China is projected to reach a market size of 1.8 trillion yuan by 2025, with a compound annual growth rate of 10% from 2014 to 2023 [8][14]. - The rehabilitation medical device market is expected to grow significantly, driven by an aging population and increasing awareness of rehabilitation services [8][14]. - The pelvic floor dysfunction (PFD) is a significant health issue for women, with a low treatment rate of only 7.9% for those affected, highlighting a substantial market opportunity for rehabilitation solutions [8][14]. Product Lines - The company’s product lines include pelvic and gynecological rehabilitation devices, reproductive rehabilitation, and anti-aging products, utilizing technologies such as ultrasound, laser, and electrical stimulation [8][14]. - Key products include biofeedback stimulators, ultrasound diagnostic systems, and portable rehabilitation devices, widely used in gynecology and rehabilitation centers [8][14]. Research and Development - The company emphasizes innovation in its product offerings, integrating AI and clinical data to provide personalized treatment plans in pelvic rehabilitation [14][15]. - Continuous investment in R&D has led to the development of advanced treatment systems, including a non-invasive pelvic muscle monitoring system [15][16]. Market Expansion - The company is actively expanding its global market presence, participating in international conferences to stay updated on technological advancements and market demands [17]. - A focus on building a comprehensive health management system for women is part of the company's strategy to enhance service offerings [17].